Tang Ren-Bin, Chang Jia-Kan, Chen Hui-Lan
Division of Pediatrics, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC; National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC.
Division of Pediatrics, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC; National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC.
J Chin Med Assoc. 2015 Mar;78(3):154-7. doi: 10.1016/j.jcma.2014.08.015. Epub 2015 Jan 6.
Probiotics are proprietary formulations of specific microorganisms and quantified populations of live bacteria that are intended to confer a health benefit on the host. These different strains and combinations of microorganisms have a wide and varying range of clinical and immunologic capacities that can modify intestinal microbial populations in ways that can benefit the host. The enhanced presence of probiotic bacteria in the intestinal microbiota has been found to correlate with protection against atopy. The prevalence of allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis has increased sharply over the past 2-3 decades in many countries, and allergies are now the most common chronic disease among children throughout the world. In the past few years, probiotics have been advocated for the management of allergic diseases in many parts of the world. So far, probiotics have shown more promise, albeit limited, in the primary prevention of allergic disease rather than in the treatment of established disease.
益生菌是特定微生物的专利配方和定量的活细菌群体,旨在给宿主带来健康益处。这些不同的微生物菌株和组合具有广泛且各异的临床和免疫能力,能够以有益于宿主的方式改变肠道微生物群。已发现肠道微生物群中益生菌的增加与预防特应性疾病相关。在过去二三十年里,许多国家哮喘、过敏性鼻炎和特应性皮炎等过敏性疾病的患病率急剧上升,过敏症如今是全球儿童中最常见的慢性病。在过去几年中,世界许多地方都提倡使用益生菌来管理过敏性疾病。到目前为止,益生菌在过敏性疾病的一级预防中显示出了更多前景,尽管有限,但在已确诊疾病的治疗方面效果欠佳。